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Development of viral resistance to the antiretroviral drugs used
for treating human immunodeficiency virus (HIV) infections is
an important cause of treatment failure and limits the options
for alternative antiretroviral regimens [1–4]. This resistance
develops gradually in a stepwise series of mutations. The num-
ber and the pattern of mutations influence the level of pheno-
typic resistance, which in some cases results in cross-resistance
to two or more drugs [5–7]. Aggressive multidrug regimens are
currently being introduced into HIV-positive pediatric popu-
lations, both in clinical practice and in controlled trials [8,9]. It
is not yet clear whether the experience and guidelines
developed for adults will be applicable to infants and children
[10]. Detection of genotypic resistance, which would be faster
and cheaper than phenotypic studies, may help in choosing an
initial regimen or in deciding to change the antiretroviral ther-
apy for a patient. Our objectives were to detect genotypic
resistance to the antiretroviral nucleoside analogs among the
perinatally HIV-1-infected children treated at our hospital and
to determine if the changes implemented in treatment regimens
would influence plasma RNA, CD4+ lymphocyte count and
disease progression.
Eleven perinatally infected children treated at the Pediatric
Infectious Diseases Section of the University Hospital ‘Virgen
Macarena’ (Seville, Spain) were included in the study and were
subsequently followed and evaluated quarterly by analyzing
their plasma RNA, CD4+ lymphocyte counts, genotypic resist-
ance to nucleoside analogs and clinical state. During the study,
the patients were treated with different antiretroviral regimens
after an individualized analysis of their previous parameters,
intolerance to drugs and disease progression.
Viremia levels were determined in batches using EDTA-
treated plasma samples, stored in aliquots at 70 °C, using
the Amplicor HIV-1 Monitor test (Roche Molecular System,
Basel, Switzerland) according to the manufacturer’s instruc-
tions, with a detection limit of approximately 200 HIV-1 RNA
copies/mL. Those samples with a viremia level of 200 copies/
mL were retested using a modification of the Amplicor HIV
Monitor test (Ultra Direct assay) with a detection limit of 20
HIV-1 RNA copies/mL [11].
Total fresh blood was used for CD4+ lymphocyte counts.
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CD4+ cell percentage and absolute counts were measured at
the same points in time as HIV-1 RNA. Flow cytometry was
performed according to standard techniques.
RNA extraction was performed with the High Pure Viral
RNA kit (Boehringer Mannheim GmbH, Mannheim, Germ-
any). cDNA synthesis and PCR amplification were performed
with the Titan System RT-PCR (Boehringer Mannheim
GmbH), following the instructions of the manufacturer and
using nested primers (Murex Innogenetics, Madrid, Spain) to
amplify the HIV-1 reverse transcriptase. Detection of nucleo-
side mutations was performed with the LIPA hybridization
assay LIPA HIV-1 RT (Murex Innogenetics). The system is
based on amplification of a fragment of the HIV RT gene by
PCR and hybridization with specific probes, fixed to a plastic
strip, which recognize and discriminate between mutant and
wild-type genotypes at positions 41, 69, 70, 74, 184 and 215
[12].
The characteristics of the 11 children included in the analysis
are shown in Table 1. The median age at entry in the study
group was 2 years (range 0.1–11 years). The majority of the
children (73%) were classified as symptomatic (stages B or C)
according to the revised 1994 Centers for Disease Control and
Prevention [13] classification of HIV infection in children.
Three were classified as stage N (two N2 and one N1). The
CD4+ lymphocyte count at baseline showed an age-dependent
downward trend that was independent of the clinical stage and
corroborated the results obtained by other authors [14–16].
This decline is possibly due to the combined effect of disease
progression and the natural fall with age. All 11 children had
detectable HIV-1 RNA at baseline. The median and geometric
mean were 5.12 and 4.89 log10 copies/mL, respectively, with a
range from 4.11 to 5.81, similar to that of children in other
reports [17–19]. The mean value of the viral load in patients
with resistance before a treatment change was 5.02 log10
copies/mL, and 4.43 log10 copies/mL following treatment
change after resistance had been detected. In those patients who
did not develop resistance, the mean after treatment was 4.2
log10 copies/mL.
Three children (patients 1, 4 and 6) had not received anti-
retroviral treatment before entry into the study. The other eight
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Table 1 Characteristics of the patients at study entry
Patient CD4+ Log10 RNA CDC clinical Treatment before Primary Resistance
no. Agea Sex (cells/mL) copies/mL stage studyb resistance developed
1 1.1 F 1494 5.12 N2 None None ZDV (K70R)
2 5 M 390 4.56 N2 ZDV + ddI None ZDV (T215Y)
3 5 F 223 5.16 C3 ZDV + ddI ZDV (T215Y) ZDV (T69D + M41L)
4 0.2 F 3071 5.29 B1 None None None
5 0.9 M 2000 4.08 B1 ZDV + ddI None None
6 4 M 646 4.47 B1 ZDV + ddI + RTV None None
7 0.2 F 3841 5.81 N1 None None None
8 0.8 F 1110 4.56 C3 ZDV + ddI None ZDV (T215Y)
9 2 M 814 4.11 B2 ZDV None None
10 7 F 150 5.42 B1 ZDV + ddI None None
11 11 F 28 5.66 C3 ZDV + ddl None None
a Age in years. b ZDV, zidovudine; ddI, didanosine; RTV, ritonavir.
children had undergone different treatment regimens: one child
had been treated with zidovudine (ZDV) alone; six children
with ZDV plus didanosine (ddI); and one child with ZDV, ddI
and ritonavir (RTV). During the study, all the children received
antiretroviral therapy: six were treated with triple therapy; four
with double therapy, and only one with ddI alone, because of
intolerance to most of the available drugs.
Of the children without previous treatment, none showed
any mutation conferring resistance to the antiretroviral drugs
investigated at study entry. Among the eight pretreated chil-
dren, one—patient 3—showed evidence of ZDV resistance
(T215Y mutation) at study entry—after only 15 days of ZDV
treatment—and developed two new mutations, T69D and
M41L, after 4 months of treatment with ZDV and ddI. Another
three children developed ZDV resistance during treatment: in
one child—patient 1—the viral population showed a K70R
mutation, but this mutation disappeared after a triple therapy
regimen was established; the other two children showing resist-
ance—patients 2 and 8—presented a T215Y mutation.
This study provides information on HIV-1 resistance in
vertically infected children of different ages and at different
clinical stages. When a genotypic mutation was detected, the
treatment regimen was changed, eliminating ZDV and adding
another nucleoside analog and/or a protease inhibitor. These
changes always produced a decrease in the copies/mL present
in the patients in later samples. In the present study, the patients
whose treatment regimens were changed after detection of a
resistant mutation had a mean 1.5 log decrease (range 1–2) in
HIV-1 RNA levels within 2 months of the change of therapy.
The results of the test to detect genotypic resistance were always
available before the viral load increased, demonstrating that
detection of resistance mutants could be more relevant in moni-
toring disease progression, although more data are needed to
confirm this observation. Moreover, since it has been dem-
onstrated [18] that rises in the HIV-1 RNA load can predict
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rapid progression to AIDS and death, it would be important to
detect resistance quickly in order to avoid this increase by an
appropriate treatment change.
Only resistance to ZDV developed in this study, probably
because ZDV was the only antiretroviral agent used alone
before resistance detection, and the most common mutation in
the RT gene was T215Y. This mutation was present in three
patients showing resistance. One patient alone showed two
other resistant mutations (M41L and T69D) to ZDV as well.
No relationship was found between development of resistance
and clinical stage.
In conclusion, in this study of vertically HIV-infected chil-
dren, very high viral loads were seen in children but with
no correlation with the clinical stage. Genotypic mutations to
resistance were detected before a change in the disease pro-
gression markers was noted (an increase of the viral load or a
decrease in CD4+ counts) and those children on a triple therapy
regimen did not develop resistance. In the absence of more
data to provide guidance on the detection of resistance to
antiretroviral drugs, pediatricians should bear in mind that the
sooner the treatment is modified to suit the individual case, the
less the possibility of viral loads rising to high levels and of the
development of resistant mutations.
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Doxycycline is a long-acting/second generation tetracycline
antibiotic, and currently is one of the most commonly pre-
scribed antibiotics in the world, used to treat a wide variety of
infectious agents including susceptible intracellular/zoonotic
pathogens [1–6].
Because doxycycline was introduced prior to an appreciation
of pharmacodynamic concepts, the optimal dosing regimen has
not been determined. This in vitro study was conducted to
determine the optimal dosing regimen for doxycycline based
upon pharmacodynamic data.
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Doxycycline was tested against selected Gram-positive patho-
gens, e.g. Staphylococcus aureus and Streptococcus pneumoniae and
Gram-negative pathogens, e.g. P. multocida and E. coli. Time-kill
studies were performed with each of these organisms at various
serum concentrations representing two, four, eight, and 16 times
the MIC of each test organism. The growth of the organisms was
assessed by colony counts at various time points during a 24 h
period to determine if doxycycline kills susceptible organisms
by concentration or time-dependent kinetics. Studies were also
carried to determine the PAE of doxycycline.
